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Stabilisation of laryngeal AL amyloidosis with long term curcumin therapy
Abstract

Multiple myeloma (MM), smoldering myeloma (SMM), and monoclonal gammopathy of undetermined
significance (MGUS) represent a spectrum of plasma cell dyscrasias (PCDs). Immunoglobulin light chain
amyloidosis (AL) falls within the spectrum of these diseases and has a mortality rate of more than 80% within
2 years of diagnosis. Curcumin, derived from turmeric, has been shown to have a clinical benefit in some
patients with PCDs. In addition to a clinical benefit in these patients, curcumin has been found to have a
strong affinity for fibrillar amyloid proteins. We thus administered curcumin to a patient with laryngeal
amyloidosis and smoldering myeloma and found that the patient has shown a lack of progression of his
disease for a period of five years. This is in keeping with our previous findings of clinical benefits of curcumin
in patients with plasma cell dyscrasias. We recommend further evaluation of curcumin in patients with
primary AL amyloidosis.
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Multiple myeloma (MM), smoldering myeloma (SMM), and monoclonal gammopathy of undetermined significance (MGUS)
represent a spectrum of plasma cell dyscrasias (PCDs). Immunoglobulin light chain amyloidosis (AL) falls within the spectrum of
these diseases and has a mortality rate of more than 80% within 2 years of diagnosis. Curcumin, derived from turmeric, has been
shown to have a clinical benefit in some patients with PCDs. In addition to a clinical benefit in these patients, curcumin has been
found to have a strong affinity for fibrillar amyloid proteins. We thus administered curcumin to a patient with laryngeal amyloidosis
and smoldering myeloma and found that the patient has shown a lack of progression of his disease for a period of five years. This
is in keeping with our previous findings of clinical benefits of curcumin in patients with plasma cell dyscrasias. We recommend
further evaluation of curcumin in patients with primary AL amyloidosis.

1. Introduction
Immunoglobulin light chain amyloidosis (AL) along with
multiple myeloma (MM), smoldering myeloma (SMM),
and monoclonal gammopathy of undetermined significance
(MGUS) represent a spectrum of plasma cell dyscrasias
(PCDs) [1]. AL is a rare and serious disorder characterized
by the deposition of amyloid fibrils in different tissues with a
mortality rate of more than 80% within 2 years of diagnosis,
particularly if associated with renal or cardiac involvement
[2, 3]. AL may coexist with any of the PCDs. It has been
reported that up to 30% of MM patients may have subclinical
amyloid deposits. In the case of SMM, no treatment will be
directed against the plasma cell clone, potentially allowing for
unbridled progression of the AL. The subtype of amyloidosis
called AL is the most heterogeneous form of the disease,
consistent with the fibril protein being unique in each patient.
Virtually any organ system excluding the brain can be affected
and in almost any combination.
Curcuma longa or turmeric is a tropical plant native to
southern and southeastern tropical Asia. It is a perennial herb

belonging to the ginger family. The most active component
in turmeric is curcumin [4]. Numerous reports suggest
that curcumin has chemopreventive and chemotherapeutic
effects. Curcumin has been shown to inhibit the proliferation
of a wide variety of tumor cells, including multiple myeloma
cells through the downregulation of IL-6 and NF-𝜅B [5].
Studies by Golombick et al. [6–9] have found that curcumin
decreases paraprotein load, bone turnover, free light chains,
and % plasma cells in the bone marrow of some MGUS and
smoldering myeloma patients. In addition to the beneficial
effects noted above, it has been suggested that curcumin
may have beneficial effects on diseases characterized by
the formation of aggregated fibrillar protein deposits [10].
Curcumin has strong affinity for fibrillar amyloid proteins
and is already used to stain in vitro tissue sections from
individuals affected with neurodegenerative disease such as
Alzheimer’s and Parkinson’s disease [11].
Based on the demonstratable effects of curcumin in
MGUS and SMM, we administered curcumin to a patient
with IgG lambda smoldering myeloma with supraglottic AL
amyloidosis. In this case report we demonstrate the beneficial
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Figure 1: Supraglottic amyloid.

effects of curcumin on the size of his laryngeal amyloid
deposit after five years of therapy.

2. Case Presentation
A 72-year-old male patient presented to the Haematology
Clinic in 2006 for evaluation of laryngeal amyloidosis,
secondary to smoldering myeloma. This was incidentally
discovered by Doppler studies after being investigated for a
cerebrovascular event. He denied symptoms of dysphagia or
dysphonia. His comorbidities included spinal canal stenosis
due to osteoarthritis, diet controlled diabetes, and hypertension. He had no history of fever, weight loss, recurrent
infections, or skeletal events. Direct laryngoscopy confirmed
an expansion of the supraglottis without evidence of soft
tissue invasion or fixation to the prevertebral tissue. This
involved mostly the region of the aryepiglottic fold and
extended down to the false vocal fold on the right side
causing effacement of the right pyriform fossa (Figure 1).
It was submucosal without ulceration. Vocal cord mobility
was normal and there was no evidence of lymphadenopathy.
Biopsies confirmed the diagnosis of amyloidosis, as an AL
type (Figure 2). A diagnosis of SMM was established by bone
marrow dyscrasia (18% plasma cell infiltration, IgG lambda)
and an elevated plasma paraprotein (14 g/L) but a negative
24-hour urine Bence Jones protein. The B2 microglobulin
(2.2 mg/L), EUC, and calcium levels were normal. A skeletal
survey, and chest, abdomen, and pelvic CT scan excluded
lytic and soft tissue lesions. Antimyeloma therapy was not
initiated as he was otherwise asymptomatic.
In 2008, repeat laryngoscopy demonstrated progressive
disease. There was a significant increase in the prominence
of the right thyroid cartilage and supraglottic swelling. The
plasma paraproteinemia (14 g/L) and free light chain ratio
remained stable and the 24-hour urine Bence Jones Protein
remained negative. A repeat bone marrow biopsy revealed
persistent plasmacytosis (18%) and negative Congo red stains
for amyloidosis. In June 2008 the patient had three courses
of melphalan (8 mg daily for 4 days) and dexamethasone
(12 mg daily for 4 days) chemotherapy which resulted in an
improvement in his paraproteinemia (6 g/L). He declined
further chemotherapy due to dexamethasone-related weight

Figure 2: Amyloid tumour of the larynx. X 40—connective tissue
partly covered by squamous mucosa. Within the connective tissue
is eosinophilic material which stains positively with Congo red. This
Congo red stained material shows apple green birefringence under
polarised light. The appearances are consistent with amyloid.

gain and secondary diabetes and melphalan-related gastrointestinal side effects and cytopenias. In 2009, he developed
worsening in back pain and was found to have CT evidence
of a sacral lytic lesion. He was treated with localised external
beam radiation therapy for pain control but with no systemic
therapy.
In 2009, the patient commenced curcumin therapy at a
dose of 1500 mg per day, gradually increasing to 3600 mg per
day. By October 2010, the supraglottic swelling had decreased
in size. In March and October 2011, the patient underwent
video assessment of the larynx and no progressive disease
was evident. The patient has remained extremely well apart
from chronic arthritic pain. MRI scans excluded new or
progressive skeletal disease, particularly his sacrum. Serial
haematological and otolaryngeal investigation, performed
annually from 2010 to 2014, has demonstrated stable disease.
The biomarkers performed over a 5-year period on curcumin
therapy are outlined in Table 1.

3. Discussion
The amyloidoses are a group of diseases that have in common
the extracellular deposition of pathologic, insoluble fibrils in
various tissues and organs. The fibrils have a characteristic 𝛽pleated sheet configuration. Many different proteins can form
amyloid fibrils, and the types of amyloidosis are classified on
the basis of the amyloidogenic protein as well as by the distribution of amyloid deposits being either systemic or localized
[12]. In the systemic form, the amyloidogenic protein is
produced at a site that is distant from the site of deposition.
In contrast, in localized disease, the amyloidogenic protein is
produced at the site of deposition.
Light chain (AL) amyloidosis is the most common type of
systemic amyloidosis and appears to be more common than
previously thought [2, 13]. The amyloidogenic protein in AL
amyloidosis is an Ig light chain or a fragment of a light chain
that is produced by a clonal population of plasma cells in the
bone marrow. Plasma cell burden in this disorder varies and
is typically 5 to 10% [3] and in approximately 10 to 15% of
patients, AL amyloidosis occurs in association with multiple
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Table 1: Haematological and biochemical data performed at first visit (February 2006) and at 3 months (2009) after commencing curcumin
therapy and thereafter annually (2010–2014).
Variable
Bone marrow biopsy (% plasma cells)
Paraprotein (g/L)
Free light chain ratio (0.3–1.7)
Lambda FLC (<26.3 mg/L)
Kappa FLC (<19.4 mg/L)
Globulin (22–38 g/L)
Calcium (mmol/L)
Ig G (6.2–14.4 g/L)
Ig M (0.48–3.04 g/L)
Ig A (0.6–3.96 g/L)
Haemoglobin (128–175 g/L)
WCC (4.0–11.0 × 109 /L)
Platelets (150–450 × 109 /L)
LDH (u/L)
B2 microglobulin (g/L)
Serum creatinine (60–120 𝜇mol/L)
eGFR (>89 mL/min)
u-creat (8.8–17.6 mmol/L)
u-prot (0.01–0.20 mg/day)

2006
18
14

20

157
6
236
167
2.2

2009
2
6
1.7
9
15
29
2.32
10.01
0.71
1.63
120
3.2
114
163
2.5
109
57
10.3
0.15

2010∗
5
1
1.3
4
5
23
2.34
9.5
0.85
1.68
139
4.3
164
133
3.1
135
45
8.1
0.06

March 2013
<2
Trace
0.81
37
30
30
2.46
9.5
0.87
1.42
135
6.8
171
142
3.4
127
46
6.6
0.05

March 2014
<2
Trace
0.68
40
27
30
9.4
0.95
1.35
136
6.1
174
140
3.7
117
51
0.07

∗

After 3 months of curcumin therapy.
“u-creat” refers to urinary creatinine and “u-prot” refers to urinary-protein.

myeloma [14]. It appears that both the light chain variable
region (Ig𝑉𝐿 ) germ line genes used by AL clones and the
plasma cell burden influence AL organ tropism (selection of
the site of deposition) [15].
The treatment of AL amyloidosis involves the same
chemotherapeutic agents used to treat multiple myeloma.
The goal is to reduce or stop the production of monoclonal
light chains by reducing or eliminating clonal plasma cells
[16]. Once the process of active deposition is halted, amyloid
deposits are slowly resorbed by the body. Therapy that lowers
the amyloidogenic FLC concentration can stop accumulation
of AL amyloid deposits, lead to their regression, and improve
survival. Treatment has been difficult and unsatisfactory and
has hitherto involved intensive chemotherapy [17]. Several
studies have evaluated the use of the immunomodulatory agents (thalidomide, bortezomib, or lenalidomide), in
combination with melphalan or cyclophosphamide and/or
dexamethasone in patients with AL amyloidosis [18–20].
Venner et al. [18] examined upfront therapy with cyclophosphamide, bortezomib, and dexamethasone (CVD) versus
cyclophosphamide, thalidomide, and dexamethasone (CTD)
and showed that the overall response rates were 71.0% versus
79.7% in the CVD and CTD arms, respectively, (𝑃 = 0.32)
[18]. One-year overall survival (OS) was 65.2% and 66.7%
for CVD and CTD, respectively (𝑃 = 0.87). The median
progression-free survival (PFS) was 28.0 m and 14.0 m for
CVD and CTD, respectively (𝑃 = 0.039). According to
outcomes performed at 6 months, the CR rate with CVD
was 59.6% versus 34.0% for CTD (𝑃 = 0.03). Both regimens
were unable to overcome the high rate of early deaths

in AL amyloidosis. A phase II trial of lenalidomide and
dexamethasone in the treatment of AL amyloidosis has
shown an overall haematological response rate of 67% [20].
Mahmood et al. [21] from the National Amyloidosis Centre in
the UK evaluated lenalidomide and dexamethasone therapy
for systemic AL amyloidosis following prior treatment with
thalidomide or bortezomib regimens. The overall haematological response rate was similar at 61%. These authors also
noted that long term therapy achieves a marked improvement
in organ responses and suggested that immunomodulatory
effects of lenalidomide therapy might enhance the otherwise
slow natural regression of amyloid deposits.
A recent in vitro study conducted in our laboratory
[22] found that curcumin enhances the cytotoxic effects
of lenalidomide in human multiple myeloma cells via suppression of the cereblon gene. Our findings suggest that
curcumin can not only potentiate the cytotoxic effect of
lenalidomide but also enhance the chemosensitizing effects
of this agent. Considering the similarity in the mechanisms
of action of lenalidomide and curcumin, it is possible that the
stabilisation of the amyloid deposit in this patient was due to
the long term effects of curcumin therapy.
Patients with myeloma and associated amyloid deposition
tend to progress and it is unusual for the disease to remain
indolent without chemotherapy. Our patient received only 3
months of low dose oral chemotherapy and radiation therapy
for a sacral lytic lesion and has been maintained exclusively
on curcumin therapy. The lack of progression of his laryngeal
amyloidosis and smoldering myeloma over a 5-year period is
in keeping with our previous findings of clinical benefits of
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curcumin in patients with plasma cell dyscrasias [6–9]. We
recommend further evaluation of curcumin in patients with
primary AL amyloidosis.

Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.

Acknowledgments
Thanks are due to Professor Norman Carr, Dr. Alistair
Lockhead, and Dr. Stephen Pearson for assistance with slide
preparation.

References
[1] S. Siragusa, W. Morice, M. A. Gertz et al., “Asymptomatic
immunoglobulin light chain amyloidosis (AL) at the time of
diagnostic bone marrow biopsy in newly diagnosed patients
with multiple myeloma and smoldering myeloma. A series of
144 cases and a review of the literature,” Annals of Hematology,
vol. 90, no. 1, pp. 101–106, 2011.
[2] M. A. Gertz, M. Q. Lacy, and A. Dispenzieri, “Amyloidosis,”
Hematology/Oncology Clinics of North America, vol. 13, no. 6,
pp. 1211–1233, 1999.
[3] R. A. Kyle and M. A. Gertz, “Primary systemic amyloidosis:
clinical and laboratory features in 474 cases,” Seminars in
Hematology, vol. 32, no. 1, pp. 45–59, 1995.
[4] B. B. Aggarwal, A. Kumar, M. S. Aggarwal, and S. Shisodia,
“Curcumin derived from turmeric (Curcuma longa): a spice for
all seasons,” in Phytopharmaceuticals in Cancer Chemoprevention, pp. 349–387, CRC Press, 2005.
[5] A. C. Bharti, N. Donato, S. Singh, and B. B. Aggarwal, “Curcumin (diferuloylmethane) down-regulates the constitutive
activation of nuclear factor-𝜅B and I𝜅B𝛼 kinase in human
multiple myeloma cells, leading to suppression of proliferation
and induction of apoptosis,” Blood, vol. 101, no. 3, pp. 1053–1062,
2003.
[6] T. Golombick and T. Diamond, “The potential role of curcumin
(diferuloylmethane) in plasma cell dyscrasias/paraproteinemia,” Biologics: Targets & Therapy, vol. 2, no. 1, pp. 161–163, 2008.
[7] T. Golombick, T. H. Diamond, V. Badmaev, A. Manoharan, and
R. Ramakrishna, “The potential role of curcumin in patients
with monoclonal gammopathy of undefined significance—its
effect on paraproteinemia and the urinary N-telopeptide of type
I collagen bone turnover marker,” Clinical Cancer Research, vol.
15, no. 18, pp. 5917–5922, 2009.
[8] T. Golombick, T. H. Diamond, A. Manoharan, and R. Ramakrishna, “Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study
and an open-label 8g extension study,” American Journal of
Hematology, vol. 87, no. 5, pp. 455–460, 2012.
[9] T. Golombick, T. H. Diamond, A. Manoharan, and R. Ramakrishna, “Long term use of curcumin in two smoldering multiple
myeloma patients,” Journal of Hematological Malignancies, vol.
3, no. 1, pp. 18–32, 2013.
[10] A. Monroy, G. J. Lithgow, and S. Alavez, “Curcumin and
neurodegenerative diseases,” BioFactors, vol. 39, no. 1, pp. 122–
132, 2013.

Case Reports in Hematology
[11] F. Yang, G. P. Lim, A. N. Begum et al., “Curcumin inhibits
formation of amyloid 𝛽 oligomers and fibrils, binds plaques, and
reduces amyloid in vivo,” The Journal of Biological Chemistry,
vol. 280, no. 7, pp. 5892–5901, 2005.
[12] P. Westermark, M. D. Benson, J. N. Buxbaum et al., “Amyloid
fibril protein nomenclature—2002,” Amyloid, vol. 9, no. 3, pp.
197–200, 2002.
[13] M. Skinner, V. Sanchorawala, D. C. Seldin et al., “High-dose
melphalan and autologous stem-cell transplantation in patients
with AL amyloidosis: an 8-year study,” Annals of Internal
Medicine, vol. 140, no. 2, pp. 85–I27, 2004.
[14] V. Sanchorawala, D. G. Wright, D. C. Seldin et al., “An overview
of the use of high-dose melphalan with autologous stem cell
transplantation for the treatment of AL amyloidosis,” Bone
Marrow Transplantation, vol. 28, no. 7, pp. 637–642, 2001.
[15] R. L. Comenzo, Y. Zhang, C. Martinez, K. Osman, and G.
A. Herrera, “The tropism of organ involvement in primary
systemic amyloidosis: contributions of Ig V L germ line gene use
and clonal plasma cell burden,” Blood, vol. 98, no. 3, pp. 714–720,
2001.
[16] H. J. Lachmann, R. Gallimore, J. D. Gillmore et al., “Outcome
in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following
chemotherapy,” British Journal of Haematology, vol. 122, no. 1,
pp. 78–84, 2003.
[17] R. L. Comenzo, E. Vosburgh, R. H. Falk et al., “Dose-intensive
melphalan with blood stem-cell support for the treatment of AL
(amyloid light-chain) amyloidosis: survival and responses in 25
patients,” Blood, vol. 91, no. 10, pp. 3662–3670, 1998.
[18] C. P. Venner, J. D. Gillmore, S. Sachchithanantham et al., “A
matched comparison of cyclophosphamide, bortezomib and
dexamethasone (CVD) versus risk-adapted cyclophosphamide,
thalidomide and dexamethasone (CTD) in AL amyloidosis,”
Leukemia, vol. 28, no. 12, pp. 2304–2310, 2014.
[19] D. C. Seldin, E. B. Choufani, L. M. Dember et al., “Tolerability
and efficacy of thalidomide for the treatment of patients with
light chain-associated (AL) amyloidosis,” Clinical Lymphoma,
vol. 3, no. 4, pp. 241–246, 2003.
[20] V. Sanchorawala, D. G. Wright, M. Rosenzweig et al., “Lenalidomide and dexamethasone in the treatment of AL amyloidosis:
results of a phase 2 trial,” Blood, vol. 109, no. 2, pp. 492–496,
2007.
[21] S. Mahmood, C. P. Venner, S. Sachchithanantham et al.,
“Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib
regimens,” British Journal of Haematology, vol. 166, no. 6, pp.
842–848, 2014.
[22] R. Wong, T. Golombick, T. H. Diamond, A. Manoharan, and R.
Ramakrishna, “Curcumin enhances the cytotoxic and chemosensitising effects of lenalidomide in human multiple myeloma
cells,” Journal of Hematological Malignancies, vol. 3, no. 2, pp.
1–7, 2013.

